Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma

Gary Schwartz, MD
Published: Friday, Jun 19, 2015



Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Eribulin lengthened survival by eight weeks compared to dacarbazine, which is significant in sarcoma, a disease that has never had a survival benefit from a novel therapy, says Schwartz.

Median overall survival for eribulin and dacarbazine was 13.5 and 11.5 months, respectively (HR = 0.768, 95% CI 0.618–0.954; P= 0.017). Progression-free survival was 2.6 months in both arms (HR = 0.877, 95% CI 0.710–1.085; P= 0.229).

Eribulin is approved to treat metastatic breast cancer. This study represents one of the first times it has been investigated in sarcoma.



Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Eribulin lengthened survival by eight weeks compared to dacarbazine, which is significant in sarcoma, a disease that has never had a survival benefit from a novel therapy, says Schwartz.

Median overall survival for eribulin and dacarbazine was 13.5 and 11.5 months, respectively (HR = 0.768, 95% CI 0.618–0.954; P= 0.017). Progression-free survival was 2.6 months in both arms (HR = 0.877, 95% CI 0.710–1.085; P= 0.229).

Eribulin is approved to treat metastatic breast cancer. This study represents one of the first times it has been investigated in sarcoma.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x